A Trial to Test the Safety and Efficacy of TEV-53408 in Treating Vitiligo

Summary

The primary objective of the trial is to evaluate the safety of TEV-53408 administered subcutaneously for the treatment of adults with vitiligo. A secondary objective is to further evaluate the safety of TEV-53408. The planned study period per participant is 84 weeks including a screening period (up to 4 weeks), a 24-week open-label treatment period, a 16-week washout period, and a 40-week follow-up period.

Timeline

Start

2024-11-11

Primary completion

2026-09-18

Completion

2027-06-25

Drugs

Indications